Electrophysiological investigation of the effectiveness of methylphenidate in children with and without ADHD
J Seifert1, P Scheuerpflug, K-E Zillessen
1EEG-Ep-Mapping Laboratory, Department of Child and Adolescent Psychiatry, University Hospital of Würzburg, Germany. kjp@nervenklinik.uni-wuerzburg.de
Insights
Methylphenidate (MPH) effectively treats attention deficit/hyperactivity disorder (ADHD) by normalizing brain electrical activity. This study confirms MPH
Area of Science:
- Neuroscience
- Child Psychology
- Psychopharmacology
Background:
- Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder impacting attention and behavior.
- The Continuous Performance Test (CPT) measures attention and response, correlating with brain electrical activity.
- Methylphenidate (MPH) is a common stimulant medication used to manage ADHD symptoms.
Purpose of the Study:
- To electrophysiologically confirm the clinical effectiveness of methylphenidate (MPH) in children with ADHD.
- To compare brain electrical activity patterns between hyperactive children (with/without MPH) and healthy controls using a modified CPT.
- To investigate the impact of MPH on specific event-related potential (ERP) components, particularly P3a.
Main Methods:
- Utilized a modified Continuous Performance Test (CPT) with 21-channel electroencephalography (EEG) recordings.
- Analyzed event-related potentials (ERPs) and their corresponding microstates in 17 hyperactive boys and 20 healthy controls.
- Employed reference-independent techniques and data-based segmentation to identify ERP components like P3a.
Main Results:
- Non-medicated ADHD children showed significantly lower P3a amplitudes compared to healthy controls under both positive and inhibitory stimulus conditions.
- Methylphenidate (MPH) treatment significantly increased P3a amplitudes in ADHD children.
- MPH-treated ADHD children's P3a amplitudes did not differ significantly from those of healthy controls, indicating normalized brain activity.
Conclusions:
- Methylphenidate (MPH) demonstrates a potent effect on stimulus recognition and response in children with ADHD.
- The Continuous Performance Test (CPT), specifically the CPT-OX variant, reliably measures electrophysiological correlates of MPH's clinical effectiveness.
- Electrophysiological data support the efficacy of MPH in normalizing attention-related brain activity in ADHD.
Abstract:
The Continuous Performance Test (CPT) is an appropriate instrument for assessment of correlates at the brain electrical activity level of attention and response to stimulant medication. The aim of the study was to confirm at the electrophysiological level the clinical effectiveness of methylphenidate (MPH) in children with attention deficit / hyperactivity disorder (ADHD); to this end, a comparative study of hyperactive and healthy control children was undertaken, employing a modified CPT test. Twenty-one channel ERPs from 17 hyperactive boys, with and without MPH treatment, and from 20 healthy control children were analyzed with reference-independent techniques. The resulting quasi-stabile microstates correspond to the time ranges of the conventional ERP components P100, P200 and P300 (with the subcomponents P3a and P3b) and could be discriminated by means of data-based segmentation. The P3a amplitudes of the hyperactive children, in each case with and without MPH medication, were compared with those of healthy controls. P3a segment amplitudes were significantly lower in non-medicated ADHD patients than in healthy children, both following positive and inhibitory stimulus conditions. A significant medication effect was detected following MPH treatment: segment 3 amplitudes in MPH-treated hyperactive children were not significantly different from those of healthy controls. MPH exerts a highly potent effect on stimulus recognition and resulting consequences. Application of the CPT-OX enables the reliable measurement of electrophysiological correlates of the clinical effectiveness of MPH under different stimulus conditions.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...